B
Bull
Bull · 25%IPA
$0.64
Szenariopreis
$2.070
+0.150 (+7.25%)Zum Schluss
Loading chart…
- High
- 2.235
- Open
- 2.000
- VWAP
- 2.10
- Vol
- 2.05M
- Mkt Cap
- 26.05M
- Low
- 2.000
- Amount
- 4.31M
- EV/EBITDA, TTM
- 0.00
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Bewertungskennzahlen
The current forward P/E ratio for Immunoprecise Antibodies Ltd (IPA) is -22.40, compared to its 5-year average forward P/E of -3.27.
Alphio AI Price Scenarios for IPA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
5.005-18NewsfilterInterVenn Biosciences Appoints New Board Members
8.505-18NewsfilterMindWalk Reports Significant Progress in Drug Development
4.509-03NewsfilterImmunoPrecise Changes Name to MindWalk and Reveals New NASDAQ Ticker "HYFT"
- 9.008-27Newsfilter
ImmunoPrecise Progresses with AI-Developed Universal Dengue Vaccine Initiative: Enters Preclinical Antibody Development Phase
- 9.508-04NASDAQ.COM
ImmunoPrecise (IPA) Q4 2025 Earnings Transcript
IPA FAQ — answered by Alphio AI
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.